DE

441.29

-2.37%↓

CTAS

200.41

-2.51%↓

CPRT

58.76

-1.51%↓

PAYX

140.23

-3.19%↓

FDX

205.02

-1.2%↓

DE

441.29

-2.37%↓

CTAS

200.41

-2.51%↓

CPRT

58.76

-1.51%↓

PAYX

140.23

-3.19%↓

FDX

205.02

-1.2%↓

DE

441.29

-2.37%↓

CTAS

200.41

-2.51%↓

CPRT

58.76

-1.51%↓

PAYX

140.23

-3.19%↓

FDX

205.02

-1.2%↓

DE

441.29

-2.37%↓

CTAS

200.41

-2.51%↓

CPRT

58.76

-1.51%↓

PAYX

140.23

-3.19%↓

FDX

205.02

-1.2%↓

DE

441.29

-2.37%↓

CTAS

200.41

-2.51%↓

CPRT

58.76

-1.51%↓

PAYX

140.23

-3.19%↓

FDX

205.02

-1.2%↓

Search

Ocugen Inc

Cerrado

0.67 1.52

Resumen

Variación precio

24h

Actual

Mínimo

0.64

Máximo

0.68

Métricas clave

By Trading Economics

Ingresos

-910K

-14M

Ventas

-372K

764K

BPA

-0.05

Margen de beneficio

-1,816.754

Empleados

95

EBITDA

-603K

-13M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+880.88% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

26M

202M

Apertura anterior

-0.85

Cierre anterior

0.67

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

Ocugen Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

21 abr 2025, 23:56 UTC

Adquisiciones, fusiones, absorciones

Nomura to Buy Macquarie's U.S., European Public Asset Management Business

21 abr 2025, 22:37 UTC

Adquisiciones, fusiones, absorciones

Hino Motors, Mitsubishi Fuso Moving Toward Merger, Nikkei Says

21 abr 2025, 23:58 UTC

Charlas de Mercado

Transurban on Bumpy Road During NSW Toll Review -- Market Talk

21 abr 2025, 23:46 UTC

Charlas de Mercado

Gold Rises Amid Likely Safe-Haven Demand -- Market Talk

21 abr 2025, 23:43 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

21 abr 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Decline as Uncertainty Over U.S. Trade Policy Continues -- Market Talk

21 abr 2025, 23:22 UTC

Adquisiciones, fusiones, absorciones

Nomura to Pay $1.8B for Macquarie's U.S. and European Public Asset-Management Business

21 abr 2025, 23:22 UTC

Adquisiciones, fusiones, absorciones

Nomura to Acquire Macquarie's U.S. and European Public Asset-Management Business

21 abr 2025, 22:35 UTC

Principales Noticias

Harvard Is Suing the Trump Administration -- 2nd Update

21 abr 2025, 22:02 UTC

Principales Noticias

Harvard Is Suing the Trump Administration -- Update

21 abr 2025, 21:46 UTC

Principales Noticias

Fed, Tariff Fears Send Dow Down More than 900 Points -- Update

21 abr 2025, 21:03 UTC

Principales Noticias

Harvard Is Suing the Trump Administration -- WSJ

21 abr 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

21 abr 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

21 abr 2025, 20:28 UTC

Principales Noticias

Fed, Tariff Fears Send Dow Down More than 900 Points -- WSJ

21 abr 2025, 20:24 UTC

Principales Noticias

Dow and Dollar Drop on Jitters Over Fed and TradeHeadline -- WSJ

21 abr 2025, 19:14 UTC

Charlas de Mercado

Oil Futures Give Back Pre-Holiday Gains -- Market Talk

21 abr 2025, 19:11 UTC

Charlas de Mercado

U.S. Natural Gas Falls as China Turns Elsewhere for LNG -- Market Talk

21 abr 2025, 19:07 UTC

Principales Noticias

Uber Faces FTC Lawsuit Alleging Deceptive Billing, Cancellation Practices -- Update

21 abr 2025, 18:44 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 abr 2025, 18:44 UTC

Charlas de Mercado

Trump Seen as Unlikely to Fire Powell Despite Market Jitters -- Market Talk

21 abr 2025, 18:28 UTC

Charlas de Mercado

Gold Finishes at New Record as Equities Slide -- Market Talk

21 abr 2025, 18:26 UTC

Principales Noticias

Dow Industrials, Dollar Fall on Fed and Trade Concerns -- WSJ

21 abr 2025, 16:27 UTC

Charlas de Mercado

Weaker Dollar No Longer Supporting Commodities Due to Fed Fears -- Market Talk

21 abr 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

21 abr 2025, 16:16 UTC

Principales Noticias

Dow and Dollar Drop on Jitters Over Fed and Trade -- WSJ

21 abr 2025, 16:00 UTC

Charlas de Mercado

Crocs Could Double Some Prices as Tariffs Threaten Heydude Line -- Market Talk

21 abr 2025, 15:53 UTC

Ganancias

Canadian Telcos Need to Show Pricing Discipline as Subscriber Growth Faces Challenges -- Analysis

21 abr 2025, 15:51 UTC

Charlas de Mercado

Stock Market Losses Keep Pressure On Oil Prices -- Market Talk

21 abr 2025, 15:49 UTC

Charlas de Mercado

Capital Plans, M&A in Focus When Precious Metals Miners Report -- Market Talk

Comparación entre iguales

Cambio de precio

Ocugen Inc Esperado

Precio Objetivo

By TipRanks

880.88% repunte

Estimación a 12 meses

Media 6.67 USD  880.88%

Máximo 8 USD

Mínimo 4 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ocugen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

3

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

0.6401 / 0.69Soporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

No Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.